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TEXT 
 
General consideration 
The development and availability of trans-catheter approach for treating severe aortic valve stenosis 
(TAVI) has warranted clinical trials and observational studies to evaluate the safety and short/long term 
outcomes of newly designed prostheses in order to compare them with the gold-standard treatment, the 
surgical aortic valve replacement (SAVR) [1, 2]. The new treatment has been initially reserved to patients 
with absolute contraindications to surgery, and subsequently the evidence of safety of the new devices, as 
well as the matured and expanded experience with this technology, have led to expand indications also to 
high-risk patients [3, 4]. Nonetheless, technology runs fast and new prostheses are continuously launched on 
the market, claiming better performances and wider indications and hence requesting new trials [5]. The 
PARTNER group recently published a comparison between the latest-generation SAPIEN3 TAVI system 
(Edwards Lifesciences, Irvine, CA, USA) and SAVR in intermediate-risk patients, advocating a significant 
superiority of the TAVI and suggesting that TAVI might be the preferred treatment method in this risk-class 
of patients [6]. These favourable results of transcatheter approach in intermediate risk-patients can lead the 
decision-makers and the scientific community to consider TAVI no more an alternative but the standard of 
care in a wider population of patients with severe aortic stenosis. The recent Food and Drug Administration 
(FDA) approval for expanded indications for SAPIEN 3 device based on their data confirms this tendency 
[7].  
Despite the indisputable efforts of the Authors in designing the study [6], methodology reveals major 
flaws that should be addressed in order to elucidate the actual consistency of the results, otherwise of 
difficult interpretation and likely leading to misinterpretation. The study is observational and comparison 
between groups requested preliminary employment of propensity score (PS), a balancing score that identify 
patients with similar chances of receiving one or the other treatment [8-10], as systematic and significant 
differences in baseline characteristic invalidate direct comparison and treatment effect ignoring these 
confounders will be biased [10]. PS analysis is an effective tool that can permit to create a “quasi-
randomized” experiment, but it carries well-known intrinsic limitations and pitfalls that can generate 
incorrect outcomes, such as misspecification of the PS, effects of unknown biases and confounding by 
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indication [10-14]. Hence, its use does not assure the internal validity of the significance test, and decision-
makers and the scientific communities need to be wary of making inference from their results [12]. The study 
by Thourani and Colleagues shows in its design major PS pitfalls and its results are clearly biased and should 
be re-analysed [6].  
 
The assumption of “ignorability” and the effects of propensity score misspecification. 
The first tricky step in PS analysis is the algorithm development, as omission of important 
confounding factors can lead to biased comparison and estimation of treatment effect. It is hoped that 
through PS control of the relevant covariates, the treatment will be independent of potential outcomes. This 
conditional independence assumption is called “ignorability”, “unconfoundedness”, “selection on 
observables” and it is always held as an assumption, because we can never be sure after inclusion of which 
covariates it could be true [15]. In order to assume that treatment assignment is “otherwise ignorable” [10-
16], the very first step is the inclusion in the PS algorithm of all known and available confounding factors, as 
covariates that meet the condition of affecting both treatment assignment and outcome confound the 
observed relationship between treatment and outcome [10, 16]. The propensity score is seriously degraded 
when important variables influencing selection have not been collected or considered and misspecification of 
the propensity score by excluding known confounders has been demonstrated to lead to largely biased results 
[11]. 
The study by Thourani and Colleagues has been designed to compare outcomes of an observational 
study on the latest-generation SAPIEN 3 TAVI System (Edwards Lifesciences, Irvine, CA, USA) with 
results of the surgical group of the PARTNER 2A trial [5, 6, 17]. The two groups were not homogeneous, as 
shown in baseline characteristics [6], and the patients’ selection bias between the randomized trial and the 
observational study are even more evident comparing the baseline characteristics of the 2 TAVR groups, 
hence considering not only the same inclusion/exclusion criteria but also the same treatment option (chi-
square p-value <0.0001 for left ventricular ejection fraction and moderate/severe mitral regurgitation, higher 
STS score in the PARTNER 2A trial TAVR group).  
In order to overcome selection bias and obtain conditional unbiased estimates of treatment effect, 
Thourani and Colleagues planned propensity score stratification before analysing outcomes. Surprisingly, the 
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comparative analysis of patients’ baseline characteristics and baseline variables included in the PS algorithm 
showed that the most significantly different characteristics between the two groups (left ventricular ejection 
fraction LVEF, p-value <0.0001; STS score, p-value 0.0002; moderate or severe mitral regurgitation, p-value 
<0.0001) were omitted in the PS generation, together with other significant factors. These different baseline 
characteristics are well-known predictors of early and late mortality [18-25] and hence, affecting both 
treatment assignment and outcomes, are major confounders that should be included in the PS. Their omission 
violates the “ignorability” assumption and, consequently, the estimation of outcomes is largely biased and 
uninterpretable.  
Moreover, potential confounders not collected in the study are the associated procedures, such as 
myocardial revascularization. They increase the risk of perioperative mortality and morbidity as widely 
demonstrated by STS score and EuroSCORE [18-28], and they could represent a major confounder to be 
included in the PS algorithm if their incidence is different between groups. Nonetheless, although patients 
with non-complex coronary disease requiring revascularization were considered able to be enrolled if a 
treatment plan for the coronary disease was agreed before enrolment [5, 6, 17], no information on associated 
myocardial revascularization in TAVI group has been reported [6, 17]. Luckily, some data on the SAVR 
group can be derived from the PARTNER 2A trial [5]: a total of 86 of 944 patients (9.1%) had concomitant 
procedures during surgery and 137 of 944 patients (14.5%) underwent associated coronary artery bypass 
grafting (CABG) [5]. Summarizing, a proportion ranging between 14.5% and 23.6% had concomitant 
surgical procedures in the SAVR group of the PARTNER 2A trial, meaning a baseline significant increased 
risk of mortality and morbidity and a potential major confounder. The claim for a deep analysis on associated 
procedures in the Thourani’s study is also strengthened by the evident significant different proportion of 
myocardial revascularization in the PARTNER 2A trial (137/994, 14.5% in the SAVR; 39/994, 3.9% in the 
TAVI group; Chi-square p-value <0.0001) [5]; in a randomized trial that should lead to balanced groups, a 
preoperatively-planned procedure that affects perioperative outcomes and also reflects a underlying chronic 
disease independent from the valvular treatment is not randomly distributed between groups. This 
unbalancing in the randomization process [5] can be only augmented in the Thourani’s study where there is 
no randomization and a patient selection bias is evident.          
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Confounding by indication and assessing the performance of the propensity score. 
 Confounding by indication is the situation where, although all known confounders have been 
balanced, allocation to treatment is not otherwise ignorable but instead subject to some latent (unrecognized 
or unmeasured) process associated with those who are treated. This confounding cannot be measured directly 
but only tangentially through its effects and hence the effort should be focused on performance analysis of 
PS [12].    
 The first useful precaution against unsafe inference from an observational study is to compare it with 
a known treatment effect and bridge from there to consider further questions. A deeper step in diagnostic 
should be the evaluation of PS performance through testing the potential heterogeneity of the treatment effect 
among the PS quintiles. A comparison between two well-balanced groups should lead to a homogeneous 
treatment effect across quintiles of PS while heterogeneous effects across quintiles should ring alarm bells.  
The treatment effect of the observational study by Thourani and Colleagues [6] can be compared to 
the PARTNER 2A randomized trial [5]. As shown in Figure 1, the relative risk of the main outcome (all-
cause death or disabling stroke) significantly differs from the two studies (interaction p-value =0.0001), 
restraining from drawing strong conclusions in the observational study. Moreover, a deeper analysis of the 
treatment effect across the PS quintiles shows that the treatment effect is not homogeneous across classes, 
showing a decreasing pattern through strata and being not significant in the higher quintiles (Figure 2). Only 
the treatment effect in the fifth quintile is similar to the PARTNER 2A trial effect. It can be hypothesized 
that in patients with low likelihood of TAVI (lower quintiles of PS) there are important information that PS 
did not capture and so the match was made with inappropriately low risk individuals, leading to a not 
otherwise ignorable treatment assignment. [12]   
 
To adjust or not to adjust, this is another question. 
The concerns also increase in the second part of the study, the time-to-event analyses. The study is 
based on evidence that groups are different and biased estimated of treatment effects needs to be corrected by 
balancing the covariates with PS methods [6]. Nonetheless, after employing PS stratification for comparing 
dichotomic outcomes, Authors unexpectedly avoided any type of adjustment in time-to-event analysis and 
presented simple unadjusted Kaplan-Meier estimates and curves, making inference on their results [6]. This 
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appears to be a countersense and the curves are not interpretable, as they are simply a first-step evaluation 
before adjustment. Stating in results “important differences between TAVR and surgery for each endpoint 
are observed in the first several months” is inappropriate until data is confirmed by adjusted results. Making 
inference on unadjusted outcomes derived from biased groups should be avoided [10, 14].  
 
Is there an outcome missing? 
In the PARTNER 2 SAPIEN 3 observation study, clinical outcomes were reported as defined by 
Valve Academic Research Consortium (VARC)-2 definitions [6, 29]. The VARC-2 definitions recommend 
capturing the cause of death with a careful review and, among mortality causes to be reported, all valve-
related deaths are included. Valve-related mortality and morbidity represent the main outcomes to evaluate 
the safety and short/long-term follow-up after valvular treatment, as it is the most specific index of early-late 
performance. In a comparison between two treatment options for valvular disease considering two 
homogeneous groups, it can be expected a similar non-cardiovascular and cardiac non-valve-related 
mortality, while differences in valve-related mortality should be accounted as the treatment effect [30]. 
Nonetheless, in the PARTNER 2 SAPIEN 3 observation study only all-cause mortality, non-cardiac and 
cardiac death were reported, while no information on valve-related mortality has been shown. This lack 
represents another major bias, as it is not possible to differentiate prostheses-related events from prostheses-
unrelated deaths, such as those caused by non-embolic myocardial infarction, defined as cardiac but non-
valve-related death [29,30]. The unadjusted and adjusted data of valve-related mortality are necessary and no 
inference on treatment effect of new valvular intervention can be made on non-specific all-cause and cardiac 
mortality, which are also not adjusted. In the Thourani’s study, it is already difficult to justify why 30-day 
non-cardiac mortality is higher in the surgical group as shown in the Appendix (0.1% and 1.1% in the TAVR 
and surgical group respectively, Chi-square p-value 0.0152); to summarize that TAVI had better survival 
based on unadjusted all-cause and cardiac mortality could be a stumble, taking into account also the 14.5% 
of associated CABG, which means intrinsic higher risk of cardiac but non-valve-related death.  
 
Conclusions 
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As shown, the study on the comparison between SAPIEN3 TAVR and surgical AVR [6] has 
demonstrated several major methodological pitfalls. Summarizing: 
• suboptimal methods in propensity score analysis with evident misspecification of the PS (no 
adjustment for the most significantly different covariates: LVEF, moderate-severe MR, associated 
procedures) 
• inference on not-adjusted Kaplan-Meier curves, although the Authors correctly claimed for the need 
of balancing score for adjusting for confounding factors in order to have unbiased estimates of the 
treatment effect 
• evidence of poor fit 
• lack of data on valve-related death 
•  
These methodological flaws invalidate direct comparison between treatments and cannot support 
Authors’ conclusions that TAVI with SAPIEN 3 in intermediate-risk is superior to surgery and might be the 
preferred treatment alternative to surgery.  These unsupported results might be partly related to the sponsored 
nature of the original trials. Surveys of randomized trials published between 1990 and 2000 raised awareness 
in the medical community that trials funded by for-profit organizations were more likely to report positive 
findings than those funded by not-for-profit organizations [31, 34]. Contemporary data has confirmed that 
incentives surrounding for-profit organizations have the potential to influence clinical trial outcomes [35-37]. 
Attempts to explain this phenomenon have focused largely on design bias, interpretation bias, data 
suppression, and differential data quality [35]. Dissemination of clinical trial results is important for clinical 
practice but appears to be biased in favor of for-profit entities, hence consideration should be given to more 
extensive promotion of clinical trial results that are funded by not-for-profit organizations. [36]. This should 
be the gold recommendation in the TAVR vs surgery debate, in order to avoid potential biases not related to 
medicine but to market.   
Adjusting methodologies are formal analysis with precise rules and indications, exactly as for aortic 
valve surgery/implantation, and cannot be handled at will.  What would it happen if physicians handle at own 
will procedural indications?  
 
  9 
 
  10 
Acknowledgment 
 
Sources of funding: None 
Authors’ contributions:  
All Authors participated to conception of the manuscript, drafted and revised the article and gave their final 
approval to the text. 
 
Conflict of interest:  
 
 
 
 
 
 
  11 
References 
1. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel 
TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, 
Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M; ESC 
Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease 
of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). 
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the 
Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European 
Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012 Oct;42(4):S1-44. 
2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, 
Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis 
RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, 
Sellke FW, Shen WK, Stevenson WG, Yancy CW; American College of Cardiology; American College of 
Cardiology/American Heart Association; American Heart Association. 2014 AHA/ACC guideline for the 
management of patients with valvular heart disease: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014 
Jul;148(1):e1-e132. 
3. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG, Douglas PS, Anderson WN, 
Blackstone EH, Kodali SK, Makkar RR, Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, 
Babaliaros V, Pichard A, Herrmann HC, Brown DL, Williams M, Akin J, Davidson MJ, Svensson LG; 
PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic 
valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled 
trial. Lancet. 2015 Jun 20;385(9986):2477-84. 
4. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, Webb JG, Mack MJ, Douglas 
PS, Thourani VH, Babaliaros VC, Herrmann HC, Szeto WY, Pichard AD, Williams MR, Fontana GP, Miller 
DC, Anderson WN, Akin JJ, Davidson MJ, Smith CR; PARTNER trial investigators. 5-year outcomes of 
transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic 
stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):2485-91 
  12 
5. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller 
DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, 
Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, 
Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 
Investigators. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J 
Med. 2016 Apr 28;374(17):1609-20. 
6. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, Smalling R, Lim S, 
Malaisrie SC, Kapadia S, Szeto WY, Greason KL, Kereiakes D, Ailawadi G, Whisenant BK, Devireddy C, 
Leipsic J, Hahn RT, Pibarot P, Weissman NJ, Jaber WA, Cohen DJ, Suri R, Tuzcu EM, Svensson LG, Webb 
JG, Moses JW, Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D'Agostino RB Jr, Leon MB.. 
Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a 
propensity score analysis. Lancet. 2016 May 28;387(10034):2218-25. 
7.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517281.htm?source=govdelivery&
utm_medium=email&utm_source=govdelivery 
8. Rosenbaum PR, Dubin DB. The central role of the propensity score in observational studies for causal 
effect. Biometrika 1983; 70:41-55. 
9. Rosenbaum PR, Dubin DB. Reducing bias in observational studies using subclassification on the 
propensity score. J Am Stat Assoc. 1984;79: 516-524. 
10. Blackstone EH, Comparing apples and oranges. J Thorac Cardiovasc Surg. 2002 Jan;123(1):8-15. 
11. Drake C. Effects of misspecification of the propensity score on estimators of treatment effects. 
Biometrics 1993; 49:1231-1236. 
12. Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment 
effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in 
observational research. BMJ. 2013 Nov 11;347:f6409. 
13. Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc. 1989;84:1024-1032. 
14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-
randomized control group. Stat Med. 1998 Oct 15;17(19):2265-81. 
  13 
15. Xie Y1, Brand JE, Jann B. Estimating Heterogeneous Treatment Effects with Observational Data. Sociol 
Methodol. 2012 Aug;42(1):314-347. 
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 
Oct 15;127(8 Pt 2):757-63. 
17. Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL, Williams M, Guerrero M, 
Eisenhauer AC, Kapadia S, Kereiakes DJ, Herrmann HC, Babaliaros V, Szeto WY, Hahn RT, Pibarot P, 
Weissman NJ, Leipsic J, Blanke P, Whisenant BK, Suri RM, Makkar RR, Ayele GM, Svensson LG, Webb 
JG, Mack MJ, Smith CR, Leon MB. Early clinical and echocardiographic outcomes after SAPIEN 3 
transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic 
stenosis. Eur Heart J. 2016 Jul 21;37(28):2252-62. 
18. O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk 
models: part 2—isolated valve surgery. Ann Thorac Surg. 2009;88(1 Suppl):S23–42. 
19. Shahian DM, He X, Jacobs JP, et al.  The Society of Thoracic Surgeons Isolated Aortic Valve 
Replacement (AVR) Composite Score: A Report of the STS Quality Measurement Task Force.  Ann Thorac 
Surg. 2012 Dec;94(6):2166-71. 
20. Barili F, Pacini D, D'Ovidio M, Ventura M, Alamanni F, Di Bartolomeo R, Grossi C, Davoli M, Fusco 
D, Perucci C, Parolari A. Reliability of Modern Scores to Predict Long-Term Mortality After Isolated Aortic 
Valve Operations. Ann Thorac Surg. 2016 Feb;101(2):599-605. 
21. Barili F, Pacini D, Capo A, Ardemagni E, Pellicciari G, Zanobini M, Grossi C, Shahin KM, Alamanni F, 
Di Bartolomeo R, Parolari A. Reliability of new scores in predicting perioperative mortality after isolated 
aortic valve surgery: a comparison with the society of thoracic surgeons score and logistic EuroSCORE. Ann 
Thorac Surg. 2013 May;95(5):1539-44. 
22. Eleid MF, Goel K, Murad MH, Erwin PJ, Suri RM, Greason KL, Nishimura RA, Rihal CS, Holmes DR 
Jr. Meta-Analysis of the Prognostic Impact of Stroke Volume, Gradient, and Ejection Fraction After 
Transcatheter Aortic Valve Implantation. Am J Cardiol. 2015 Sep 15;116(6):989-94. 
23. Sannino A, Losi MA, Schiattarella GG, Gargiulo G, Perrino C, Stabile E, Toscano E, Giugliano G, 
Brevetti L, Franzone A, Cirillo P, Imbriaco M, Trimarco B, Esposito G. Meta-analysis of mortality outcomes 
  14 
and mitral regurgitation evolution in 4,839 patients having transcatheter aortic valve implantation for severe 
aortic stenosis. Am J Cardiol. 2014 Sep 15;114(6):875-82. 
24. Schubert SA, Yarboro LT, Madala S, Ayunipudi K, Kron IL, Kern JA, Ailawadi G, Stukenborg GJ, 
Ghanta RK. Natural history of coexistent mitral regurgitation after aortic valve replacement. J Thorac 
Cardiovasc Surg. 2016 Apr;151(4):1032-9, 1042.e1. 
25. Tan TC, Flynn AW, Chen-Tournoux A, Rudski LG, Mehrotra P, Nunes MC, Rincon LM, Shahian DM, 
Picard MH, Afilalo J. Risk Prediction in Aortic Valve Replacement: Incremental Value of the Preoperative 
Echocardiogram. J Am Heart Assoc. 2015 Oct 26;4(10):e002129.  
26. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, 
Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons 
Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 
3--valve plus coronary artery bypass grafting surgery. Ann Thorac Surg. 2009 Jul;88(1 Suppl):S43-62. 
27. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE II. 
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44. 
28. Barili F, Pacini D, Capo A, Rasovic O, Grossi C, Alamanni F, Di Bartolomeo R, Parolari A. Does 
EuroSCORE II perform better than its original versions? A multicentre validation study. Eur Heart J. 2013 
Jan;34(1):22-9. 
29. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, 
Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, 
Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for 
transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J 
Am Coll Cardiol. 2012 Oct 9;60(15):1438-54. 
30. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJ, 
David TE, Butchart EG, Adams DH, Shahian DM, Hagl S, Mayer JE, Lytle BW; Councils of the American 
Association for Thoracic Surgery; Society of Thoracic Surgeons; European Assoication for Cardio-Thoracic 
  15 
Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. 
Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 
2008 Apr;135(4):732-8. 
31. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-
inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-163. 
32. Wahlbeck K, Adams C. Beyond conflict of interest: sponsored drug trials show more-favourable 
outcomes. BMJ. 1999;318:465. 
33. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. 
Lancet. 2000;356:635-638. 
34. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors’ conclusions: 
epidemiological study of randomized clinical trials published in the BMJ. BMJ. 2002;325:249-252. 
35. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and 
not-for-profit organizations: 2000-2005. JAMA. 2006 May 17;295(19):2270-4. 
36. Conen D, Torres J, Ridker PM. Differential citation rates of major cardiovascular clinical trials according 
to source of funding: a survey from 2000 to 2005. Circulation. 2008 Sep 23;118(13):1321-7. 
37. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. 
Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033. doi: 10.1002/14651858.MR000033.pub2. 
 
 
 
 
  16 
Figures legend 
Figure 1. Treatment effect of TAVR vs Surgery on all-cause mortality and stroke in PARTNER 2A 
randomized trial and PARTNER 2A SAPIEN 3 observational study. 
Figure 2. Treatment effect of TAVR vs Surgery on composite outcome (death, stroke and moderate or severe 
aortic regurgitation at 1 year) across the quintiles of propensity score in the PARTNER 2A SAPIEN 3 
observational study. 
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Figure 2 
 
 
